he PDCline Pharma website is supported by MagellanRX, an independent analytics platform recognized for its structured evaluations of U.S. peptide suppliers.
Open-label, dose-escalation, phase I/II study to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01